secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001193125-24-200629
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic reports Q2 net loss $12.7M; cash $185.1M; TX45 Phase 2 trial open
--------------------------------------------------------------------------

- Net loss of $12.7M for Q2 2024 vs $10.5M in Q2 2023; R&D expenses $7.1M.
- Cash and cash equivalents $185.1M as of June 30, providing runway into mid-2027.
- TX45 Phase 2 APEX trial for PH-HFpEF open for screening; first dosing expected Sept 2024.
- Closed reverse merger with AVROBIO in June 2024, with concurrent $130.7M private placement.
- Appointed Dan Lochner as CFO in June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524200629/0001193125-24-200629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524200629/d838115d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-200629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer